Your Notifications
All done, no notifications

What is Non-Hodgkin lymphoma (NHL)?

Non-Hodgkin lymphoma is a kind of cancer affecting the lymphatic system. The lymphatic system comprises organs, glands, tube-like channels, and lymph node clusters. It is a component of the body's germ-fighting immune system.

Non-Hodgkin lymphoma develops when germ-fighting cells in the lymphatic system become out of control. Tumors are growths that cells can generate throughout the body.

What is the Importance of Timely Treatment?

  • Non-Hodgkin lymphoma (NHL) should be treated immediately to improve patient outcomes. Early management helps to keep the condition from developing to later stages, which can be more challenging to treat.
  • NHL has considerably better survival rates when discovered and treated early since patients are more likely to respond successfully to medicines, including chemotherapy, immunotherapy, and targeted treatments.
  • Delays in therapy might result in problems such as organ damage and increased tumour growth, lowering the likelihood of successful management.
  • Timely NHL treatment increases the chances of remission, reduces complications, and improves overall quality of life.

What are the Common Symptoms of Non-Hodgkin lymphoma (NHL)?

Non-Hodgkin lymphoma symptoms may include the following:

  • Swollen lymph nodes in the neck, armpits, or groin
  • Persistent exhaustion
  • Chest discomfort
  • Cough
  • Difficulty breathing (dyspnea)
  • Abdominal discomfort or oedema
  • Symptoms may include feeling full despite not having eaten
  • Unexplained temperature.
  • Drenching night sweats.
  • Unexplained weight loss

Types of Non-Hodgkin lymphoma (NHL)

Non-Hodgkin lymphoma can be classified into over 70 different subgroups. Healthcare practitioners categorise them according to the type of lymphocyte affected:

  • B cell lymphoma: B cells are a type of lymphocyte that helps fight infection. B cells produce antibodies against foreign invaders. B cells are responsible for the vast majority of non-Hodgkin lymphomas. Non-Hodgkin lymphoma subtypes involving B cells include diffuse large B-cell lymphoma, follicular lymphoma, mantle cell lymphoma, and Burkitt lymphoma.
  • T cell lymphoma: T cells are lymphocytes that destroy foreign invaders directly. Non-Hodgkin lymphoma occurs substantially less frequently in T cells. Peripheral T-cell lymphoma and cutaneous T-cell lymphoma are two T-cell-related non-Hodgkin lymphoma subtypes.

Stages of Non-Hodgkin lymphoma (NHL)

Healthcare providers stage cancer to design treatment strategies and predict prognosis, which is the expected outcome. Non-Hodgkin lymphoma stages are as follows:

  • Stage I: Cancer cells are seen in one lymph node or lymphoid organ. Or there is lymphoma in a specific location of a particular organ outside your lymphatic system.
  • Stage II: Lymphoma exists in two or more groups of lymph nodes on the same side of (or near) your diaphragm.
  • Stage III: Cancer cells are found in lymph node locations above and below your diaphragm or lymph nodes above your diaphragm and in your spleen.
  • Stage IV: At least one organ outside your lymph system, such as your liver or lungs, has extensive lymphoma.

Causes, Risk Factors and Complications of Non-Hodgkin Lymphoma (NHL)

Causes

  • Non-Hodgkin lymphomas develop when your body creates an excess of lymphocytes. These comprise B cells, T cells, and (occasionally) natural killer (NK) cells. Acquired genetic alterations that influence lymphocyte development contribute to the process.
  • When lymphocytes mutate, they multiply and eventually become tumours. Usually, cancers begin in your lymph nodes. Because the lymphatic system contacts almost every body region, non-Hodgkin lymphoma frequently spreads to other lymph organs.

Risk Factors

The following factors may increase the risk of non-Hodgkin lymphoma:

  • Medicines that reduce immune response: Following an organ transplant, taking immune-modulating medications may increase the risk of non-Hodgkin lymphoma.
  • Infection with certain viruses and bacteria: A few infections appear to increase the risk of non-Hodgkin lymphoma.
  • Chemicals: Certain chemicals, such as those used to eliminate insects and weeds, can increase the risk of non-Hodgkin lymphoma.
  • Older age: Non-Hodgkin lymphoma can develop at any age. However, it is more common among those aged 60 and up.

Complications

Non-Hodgkin lymphoma and its therapies can induce a variety of problems, including:

  • Weakened immune system.
  • Fertility problems
  • Secondary Cancer
  • Organ Damage

Connect with our advisor for a PRIORITY response

Latest Research and Technologies in the Treatment of Non-Hodgkin Lymphoma (NHL) in the United Arab Emirates

  • For patients with relapsed or refractory non-Hodgkin lymphoma who are unable to receive stem cell transplantation, radioimmunotherapy has become a potentially effective treatment option. It has demonstrated positive benefits, including better survival rates and acceptable safety profiles.
  • Targeted Therapies: When used in conjunction with conventional treatments, targeted therapies, such as antibody-drug conjugates, are increasing the efficacy of treatment for aggressive forms of non-Hodgkin lymphoma by providing higher response rates and progression-free survival.

Non-Hodgkin Lymphoma (NHL) Prevention Tips

Some preventative tips for non-Hodgkin lymphoma (NHL):

  • Prevent exposure to hazardous chemicals.
  • Reduce radiation exposure from unneeded medical imaging and workplace settings.
  • Improve immunological health by eating a well-balanced diet, exercising regularly, and managing stress.
  • Prevent infection.
  • To lower the risk of NHL, limit your alcohol consumption.
  • To support immune function, eat a nutritious diet that includes fruits, vegetables, and whole grains.
  • These steps can help lower risk, but frequent health screenings are necessary for early detection.

Treatment options for Non-Hodgkin lymphoma (NHL)

Chemotherapy: Chemotherapy is an effective treatment for non-Hodgkin lymphoma that is often taken via vein or tablet and can be supplemented with targeted therapy.


Cost Start From USD 800 - USD 6000Explore Options

Immunotherapy: Immunotherapy is a medication that helps the body's immune system eliminate cancer cells, which can survive by hiding from the immune system.


Cost Start From USD 800 - USD 6000Explore Options

Targeted therapy: This targets specific molecules in cancer cells, resulting in cell death. It is frequently used in conjunction with chemotherapy for non-Hodgkin lymphoma, either as the first or second treatment if the cancer recurs.


Cost Start From USD 5500 - USD 54000Explore Options

CAR-T cell therapy: A treatment that reprograms immune system cells to combat non-Hodgkin lymphoma. It involves removing white blood cells, including T cells, from the bloodstream and processing them in a lab to produce receptors identifying lymphoma markers.


Cost Start From USD 200000 - USD 300000Explore Options

Bone Marrow Transplant: A bone marrow transplant, also known as a bone marrow stem cell transplant, entails introducing healthy bone marrow stem cells into the body. These cells restore damaged cells caused by chemotherapy and other treatments. Non-Hodgkin lymphoma patients may require a bone marrow transplant if other treatments have failed.

{bmt-autologous}

Radiation therapy: Cancer is treated using radiation therapy, which uses intense energy beams. Energy can be derived from X-rays, protons, or other sources.

  • Physical exam: A healthcare expert will examine your neck, underarms, and groin for enlarged lymph nodes, as well as your spleen or liver.
  • Blood and Urine Tests: Blood and urine tests can help rule out infections and other diseases.
  • Imaging tests: Imaging tests can detect cancer cells within your body. Depending on the location of the lymphoma cells, you may require a CT scan, MRI, ultrasound, or PET scan.
  • Biopsy: A biopsy is the only technique to determine whether abnormal cells are NHL. Your provider removes a portion of a lymph node or affected tissue. A pathologist will examine the tissue with a microscope for lymphoma cells.
  • Immunophenotyping: This test is used to diagnose particular NHL kinds. It recognises cancer cells depending on the types of antigens.
  • Lumbar puncture: A lumbar puncture removes part of the fluid surrounding the spinal cord. This operation is also known as a spinal tap. If a healthcare provider suspects the lymphoma is affecting the fluid surrounding the spinal cord, they could suggest this test.

Rehabilitation for Non-Hodgkin Lymphoma (NHL) is critical for patients' physical, mental, and social recovery after therapy. Here are the main rehabilitation options:

  • Physical therapy: Aims to enhance strength, flexibility, and mobility, particularly if the patient has experienced weariness, weakness, or joint pain as a result of treatment. It aids in restoring stamina and enhancing general physical function.
    Psychosocial Support: Emotional and psychological support, such as counselling or support groups, assists patients in coping with stress, anxiety, depression, and the emotional toll of cancer therapy.
    Dietary Management: Eating a well-balanced diet can help you retain strength, control prescription side effects, and improve overall health.
  • Cognitive Rehabilitation: Some NHL patients may develop cognitive challenges, including memory and attention issues, sometimes called "chemo brain." Cognitive therapy and exercise can aid with mental focus and clarity.
  • Occupational therapy: This helps patients restore their capacity to conduct daily duties at home or work. Occupational therapists can help alter settings or employ assistive equipment to overcome treatment-related physical restrictions.

Depending on the circumstances, your doctor may prescribe medication to assist you in managing your symptoms and support your treatment plan.

Treatment regimens are adapted to the patient's specific cancer stage and location.

Instantly Connect with our Specialists

Doctor 1
Doctor 2
Doctor 3
Doctor 4
Doctor 5
Doctor 6
Doctor 7
Doctor 8

Hospitals for Non-Hodgkin lymphoma (NHL) in United Arab Emirates

Zulekha Hospital Sharjah: Top Doctors, and Reviews
Zulekha Hospital Sharjah

Sharjah, United Arab Emirates

Zulekha Hospital Sharjah located in Sharjah, United Arab Emirates is accredited by ISO, JCI. Also listed below are some of the most prominent infrastructural details:

  • Zulekha Hospital Sharjah is present over a 290,000 square feet area.
  • The hospital stands today with a bed capacity of 185.
  • The hospital also has a Cardiac Catheterization Laboratory and radiology as well as laboratory services.
  • There is an ICU and Neonatal ICUs.
  • There are facilities for Dialysis and advanced technological applications such as Minimal Invasive surgeries.
  • In Zulekha Hospital Sharjah Bariatric procedures, Joint Replacement, Specialised Cancer Care, Cardio Thoracic and Vascular Procedure, Plastic and Reconstructive Procedure are performed.
  • It also specialises in Pediatric Cardiology, Pulmonology and Chest Diseases, etc.
  • Teleconsultation services as well as an international patient care center with related assistance for medical travelers are functioning in Zulekha Sharjah.
Burjeel Medical City: Top Doctors, and Reviews
Burjeel Medical City

Abu Dhabi, United Arab Emirates

The Hospital owns an International Patient Services Team that is responsible to assist international patients with world-class healthcare, transportation arrangement, accommodation facilities, language interpreters, and much more. 

Burjeel Medical City (about 1.2 million square facilities)provides 7-star hospitality to its patients. It has the largest facility space bed among all the private hospitals. The Hospital consists of-

  • Large waiting areas and consultation rooms 
  • Spacious lobbies on each floor 
  • 338 Luxurious Patient Rooms 
  • 70 Ambulatory Rooms
  • Intensive Care Units
  • The Hospital comprises various centers, under Burjeel Cancer Institute- 
  • Breast Center
  • Uro-oncology Center
  • Surface Malignancy Center (HIPC)
  • Head & Oncology Center
  • Medical Oncology & Hematology Center and others
Zulekha Hospital Dubai: Top Doctors, and Reviews
Zulekha Hospital Dubai

Dubai, United Arab Emirates

Zulekha Hospital Dubai located in Dubai, United Arab Emirates is accredited by ISO, JCI. Also listed below are some of the most prominent infrastructural details:

  • The bed capacity of Zulekha Hospital Dubai is 140.
  • Diagnostic centers, pharmacies, inpatient and outpatient care are provided at Zulekha Hospital Dubai.
  • This hospital provides the best of healthcare packages
  • Its surgical base is really strong with the hospital having successfully initiated and completed minimally invasive surgeries, joint replacement surgeries, bariatric surgeries, cardiac, and neonatal surgeries.
  • Radiology, laboratory, operating theatres, dialysis section and Cardiac Catheterization Laboratory are all present in Zulekha Hospital Dubai, UAE.

Our Services to better your experience

Opinion & Option

We submit the most accurate opinion and options from one or more countries for your review

Consult Privately

Consult with a certified specialist privately on our telemedicine platform even before you decide to travel

Logistics

We handle flights, visas, transfers, and accommodation—so you can focus on your health.

Recovery

Our In-house rehabilitation service packages to better your recovery and treatment outcome

Why Choose the United Arab Emirates for Chronic myeloid leukemia (CML) Treatment?

Here are some of the reasons for choosing the United Arab Emirates:

  • Expert oncologists: The United Arab Emirates has highly trained oncologists and specialised cancer centres that treat CML.
  • Advanced Treatment Options: Targeted therapies, stem cell transplants, and chemotherapy are among the latest treatments available in the country, using cutting-edge technology.
  • Cost-Effective Care: Compared to many Western countries, treatment in the United Arab Emirates is less expensive, ensuring high-quality care for a lower price.
  • International Patient Services: UAE hospitals offer seamless treatment to international patients, including multilingual support and personalised services.
  • Accredited Healthcare Facilities: The United Arab Emirates' top hospitals are JCI-accredited, ensuring the highest quality medical services.

Frequently Asked Questions

With a 90% relapse-free survival rate over three years for patients with low-risk diffuse large B-cell lymphoma (DLBCL), the United Arab Emirates has a promising success rate for treating non-Hodgkin lymphoma (NHL). Higher-risk groups, however, may have worse survival rates, highlighting the significance of early detection and individualised care. Developments in immunotherapies and targeted medicines, as well as the UAE's sophisticated healthcare system, have significantly improved patients' quality of life and survival rates.

NHL can return, particularly in aggressive forms, but with consistent treatment and surveillance, many patients can attain long-term remission. Continuous follow-up is critical for detecting relapses early.

Common side effects include nausea, exhaustion, hair loss, an increased susceptibility to infections, and mouth sores. Side effects vary depending on the treatment but are manageable with supportive care and medications.

Follow-up examinations are usually advised every three to six months following therapy. These include standard imaging scans and blood tests to screen for indications of illness progression or recurrence.

Yes, the United Arab Emirates offers cost-effective treatment for NHL while following international medical standards, making it an appealing alternative for patients seeking high-quality care at a lower cost.